Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.
Metrics to compare | SCLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSCLXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −0.5x | −0.7x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price / Book | −0.3x | 0.9x | 2.6x | |
Price / LTM Sales | 1.1x | 1.4x | 3.1x | |
Upside (Analyst Target) | - | 190.7% | 49.4% | |
Fair Value Upside | Unlock | 14.9% | 8.9% | Unlock |